JP2024509265A5 - - Google Patents
Info
- Publication number
- JP2024509265A5 JP2024509265A5 JP2023555275A JP2023555275A JP2024509265A5 JP 2024509265 A5 JP2024509265 A5 JP 2024509265A5 JP 2023555275 A JP2023555275 A JP 2023555275A JP 2023555275 A JP2023555275 A JP 2023555275A JP 2024509265 A5 JP2024509265 A5 JP 2024509265A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- item
- myelofibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160412P | 2021-03-12 | 2021-03-12 | |
| US63/160,412 | 2021-03-12 | ||
| US202163185464P | 2021-05-07 | 2021-05-07 | |
| US63/185,464 | 2021-05-07 | ||
| PCT/US2022/020038 WO2022192730A1 (en) | 2021-03-12 | 2022-03-11 | Compositions and methods for treating polycythemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509265A JP2024509265A (ja) | 2024-02-29 |
| JP2024509265A5 true JP2024509265A5 (https=) | 2025-03-11 |
Family
ID=83228388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555275A Pending JP2024509265A (ja) | 2021-03-12 | 2022-03-11 | 赤血球増加症を処置するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20260027107A1 (https=) |
| EP (1) | EP4304596A4 (https=) |
| JP (1) | JP2024509265A (https=) |
| KR (1) | KR20230169981A (https=) |
| AU (1) | AU2022233178A1 (https=) |
| BR (1) | BR112023018403A2 (https=) |
| CA (1) | CA3213395A1 (https=) |
| IL (1) | IL305806A (https=) |
| MX (1) | MX2023010449A (https=) |
| WO (1) | WO2022192730A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230169981A (ko) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | 적혈구증가증을 치료하기 위한 조성물 및 방법 |
| CN116942668A (zh) * | 2023-03-17 | 2023-10-27 | 天津医科大学 | Glyt1抑制剂在治疗器官纤维化中的应用 |
| AU2024339974A1 (en) * | 2023-09-15 | 2026-03-26 | Disc Medicine, Inc. | Glyt-1 inhibitors and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| KR20230169981A (ko) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | 적혈구증가증을 치료하기 위한 조성물 및 방법 |
-
2022
- 2022-03-11 KR KR1020237034671A patent/KR20230169981A/ko active Pending
- 2022-03-11 MX MX2023010449A patent/MX2023010449A/es unknown
- 2022-03-11 BR BR112023018403A patent/BR112023018403A2/pt unknown
- 2022-03-11 WO PCT/US2022/020038 patent/WO2022192730A1/en not_active Ceased
- 2022-03-11 AU AU2022233178A patent/AU2022233178A1/en active Pending
- 2022-03-11 US US18/280,837 patent/US20260027107A1/en active Pending
- 2022-03-11 EP EP22768132.7A patent/EP4304596A4/en active Pending
- 2022-03-11 IL IL305806A patent/IL305806A/en unknown
- 2022-03-11 JP JP2023555275A patent/JP2024509265A/ja active Pending
- 2022-03-11 CA CA3213395A patent/CA3213395A1/en active Pending
-
2024
- 2024-03-05 US US18/596,341 patent/US20240269132A1/en not_active Abandoned
- 2024-10-23 US US18/923,904 patent/US20250248995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024509265A5 (https=) | ||
| Gangat et al. | JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management | |
| JP7065115B2 (ja) | フェロポーチン阻害剤塩 | |
| EP3415502B1 (en) | Substituted heteroaryl compound, composition containing same, and application thereof | |
| CN110372670B (zh) | 治疗活性化合物及其使用方法 | |
| KR102907811B1 (ko) | 히노키티올 유사체, 이의 제조 방법 및 약제학적 조성물 | |
| KR20010051181A (ko) | 신경병증의 치료 | |
| AU2015324158A1 (en) | Therapeutically active compounds and their methods of use | |
| US20240269132A1 (en) | Compositions and methods for treating polycythemia | |
| WO2021013771A1 (en) | Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt) | |
| CA3205845A1 (en) | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) | |
| Hamed et al. | Recent progress in gene therapy and other targeted therapeutic approaches for beta thalassemia | |
| JP2024521578A5 (https=) | ||
| Locatelli et al. | The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors | |
| CN108623528B (zh) | 一种取代的嘧啶三酮化合物及包含该化合物的组合物及其用途 | |
| Tacke et al. | Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease | |
| US20130316998A1 (en) | Method for treating pancreatic cancer | |
| JP2015529660A (ja) | 新規な化合物およびその使用 | |
| CN121311605A (zh) | 通过kras突变来关联akr1c3酶表达水平及医药用途 | |
| CA3113408A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
| JP2020023447A (ja) | フェニルテトラヒドロピリドインドール誘導体及び医薬組成物 | |
| KR20140027196A (ko) | 철 결핍 증상 및 철 결핍성 빈혈의 치료 및 예방용 Fe(III) 착화합물 | |
| KR20150134353A (ko) | 철 결핍 증상과 철 결핍성 빈혈의 치료와 예방용 철 (iii) 착 화합물 | |
| EP3315487B1 (en) | Novel platinum (iv) complex | |
| EP4599885A2 (en) | Compounds for the treatment of glioblastoma |